Bio-Rad Laboratories (BIO) has moved into focus after its second quarter 2026 earnings and fresh guidance, which combined a slight overall revenue decline with firmer contributions from several international markets.

The recent guidance and international revenue patterns arrived alongside a sharp shift in sentiment around Bio-Rad Laboratories, with a 46.30% 90 day share price return and a 29.66% 1 year total shareholder return contrasting with a weaker 5 year total shareholder return that declined 54.35%. This suggests that momentum has picked up only in the shorter term around the latest results and outlook.

If Bio-Rad Laboratories' recent move has you looking for other potential growth stories in health related technology, this could be a useful moment to scan 43 healthcare AI stocks

After a 46.30% move in 90 days, Bio-Rad Laboratories now sits well above its recent lows. The next step is to weigh paying up for this momentum against waiting for a pullback as current valuation metrics come into focus.

Most Popular Narrative: 21.6% Overvalued

Against the most followed fair value estimate of $293, Bio-Rad Laboratories' last close at $356.25 sits well above that narrative anchor, which is built on detailed assumptions about growth, margins and valuation multiples.

Robust order growth and increased guidance in Bio-Rad's process chromatography business reflect the ongoing global investment in biopharmaceutical research and manufacturing, a trend likely to fuel sustainable double-digit revenue increases and improved operating leverage as new biologics and therapeutics expand the market.

Want to see what the narrative is baking in to justify that premium for Bio-Rad Laboratories? The story leans on measured revenue growth, firmer margins and a richer future earnings multiple that pushes well ahead of the broader life sciences group.

Result: Fair Value of $293 (OVERVALUED)

However, Bio-Rad Laboratories still faces pressure from softer instrument demand and margin compression, which could challenge the premium narrative if these headwinds persist.

Next Steps

If the mixed signals around Bio-Rad Laboratories leave you unsure, this is a good time to review the data yourself and move quickly to shape your own view. A useful place to start is by checking the 1 important warning sign

Looking for more investment ideas beyond Bio-Rad Laboratories?

Do not stop with just one stock. Use this moment of focus on Bio-Rad Laboratories to widen your watchlist and line up your next potential opportunities.

• Sharpen your value hunting by checking companies that look mispriced on quality and fundamentals through the 51 high quality undervalued stocks.
• Strengthen your focus on resilience by reviewing stocks highlighted in the 83 resilient stocks with low risk scores.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems before these opportunities gain wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.